• Welcome to FZATA
  • Company

    Business Model

    FZata will develop one or more novel potent antibody and move it through pre-IND package stage or Phase I clinical trials; We will then partner or out-license it out to big pharma; then we will use revenues generated to reinvest to advance other pipeline drug candidates.

    Currently our C. diff toxin antibodies are the front in our pipeline. We will use them as our launch pad to complete our business model.